Drug Profile
Timolol ophthalmic - Betaliq
Alternative Names: BTQ-1902Latest Information Update: 31 Mar 2023
Price :
$50
*
At a glance
- Originator Betaliq
- Class Amino alcohols; Antiglaucomas; Antihypertensives; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Small molecules; Thiadiazoles
- Mechanism of Action Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 31 Dec 2022 Betaliq plans a phase III trial for Ocular hypertension and Open-angle glaucoma in 1H of 2023 (Novaliq pipeline, December 2022)
- 29 Apr 2022 Betaliq completes a phase II trial in Ocular hypertension and Open-angle glaucoma in USA (Ophthalmic) (NCT04910100)
- 15 Apr 2021 Phase-II clinical trials in Ocular hypertension in USA (Ophthalmic) (NCT04910100)